Irritable Bowel Syndrome, Quality of Life, Relief of Irritable Bowel Syndrome Symptoms
Conditions
Keywords
IBS (Irritable Bowel Syndrome), Probiotic yoghurt, Symptom severity
Brief summary
To determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo. To determine the effect of cultura yoghurt on change in total score of (IBS) irritable bowel syndrome severity index during 8 weeks of treatment in comparison to placebo in IBS out patients.
Detailed description
Recent research has shown taht probiotic may give positive effect on symptoms among patients with (IBS) Irritable Bowel Syndrome. The mechanism behind the positive effect are not known but a positive effect on different cytokines are a possible mechanism. Also effect on the large intestine bacterial mass could be of importance.
Interventions
OTHERArla Yoghurt with no probiotic
two servings of 200 ml of investigational products per day
OTHERProbiotic yoghurt (Cultura)
200 ml per day
Sponsors
Good Food Practice, Sweden
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Signed consent to participate age 18-70 years IBS according to Rome II criteria \-
Exclusion criteria
1. Participation in a clinical study one month prior to screening visit and throughout the study. 2. Abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the investigator. 3. Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by the investigator. 4. Other severe disease(s) such as malignancy, severe coronary disease, kidney disease or neurological disease, as judged by the investigator. 5. Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss of weight or fever, as judged by the investigator. 6. Severe psychiatric disease as judged by the investigator. 7. Previous history of drug or alcohol abuse six months prior to screening. 8. Intolerance or allergy against milk products or gluten. 9. Use of other probiotic products (according to sponsor's list) 2 weeks prior to the study and throughout the study. 10. Consumption of antibiotic drugs 1 month prior to screening and throughout the study. 11. Consumption of cortisone, NSAID or other anti-inflammatory drugs on a regular basis 2 weeks prior to screening and throughout the study. 12. Pregnant or lactating or wish to become pregnant during the period of the study. 13. Lack of suitability for participation in the study for any reason as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relief of IBS symptoms | 6 weeks intervention and 6 weeks follow up | The primary endpoint of this study was the proportions of patients reporting adequate relief of their IBS symptoms at least 50 % of the weeks during the treatment period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects on gastrointestinal and extraintestinal symptoms | September 2005 to May 2006 | effects of the investigational products on GI and extraintestinal symptoms assessed with the weekly IBS SSI questionnaire and the scores from the daily questions of the GI symptom questionnaire as weel as the effect on psychological symptoms and quality of life. |
Countries
Sweden
Outcome results
None listed